AzTrials
AzTrials

Alcohol IntoxicationPhase 1NCT00608686

Neurosteroids and Acute Alcohol Intoxication in Humans

A Phase 1 study testing Pregnenolone in people with Alcohol Intoxication, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA) at 1 site in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

1. The major aims are to assess: (1) the relationship of basal and alcohol-induced neurosteroid and GABA levels to the degree of acute alcohol intoxication in healthy male and female volunteers; and (2) the effect of acute pregnenolone administration on the degree of acute alcohol intoxication in these same… Read more about this study

Who is it for?
Ages 21 to 45 yearsHealthy volunteers can take part
Conditions the study is for
Alcohol Intoxication
What is being tested?
Pregnenolone
Type of treatment
Pill or oral medicine
How many people
92 participants
Where
1 siteUnited States
Study dates
May 2004to Mar 2009
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 45 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • drinks alcohol more than 6 times a year.
  • can understand english well enough to perform the required tasks.
  • is in general good health.

Who cannot join

  • having a member of immediate family who is alcoholic.
  • using drugs that would interfere with study.
  • not able to tolerate 3 alcoholic drinks within 30 minutes.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of California, San Francisco

    San Francisco, California, 94143

Other trials in United States

About this study

  1. The major aims are to assess: (1) the relationship of basal and alcohol-induced neurosteroid and GABA levels to the degree of acute alcohol intoxication in healthy male and female volunteers; and (2) the effect of acute pregnenolone administration on the degree of acute alcohol intoxication in these same volunteers. Specific hypotheses are:
  • Baseline serum levels of pregnenolone, pregnenolone sulfate (PS), dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEA-S) will be inversely correlated with the magnitude of acute behavioral responses to alcohol (sedation, anxiolysis, amnesia, psychomotor impairment and intoxication). That is, higher baseline levels of these neurosteroids will be associated with lessened behavioral responses to alcohol.
  • Baseline serum levels of allopregnanolone, tetrahydrodeoxycorticosterone (THDOC), androstanediol, androsterone and GABA will be directly correlated with the magnitude of acute behavioral responses to alcohol. That is, higher baseline levels of these substances will be associated with heightened behavioral responses to alcohol.
  • Acute alcohol ingestion, compared to placebo ingestion, will increase serum levels of allopregnanolone and THDOC and plasma levels of GABA and will decrease plasma levels of PS. (Effects on levels of other neurosteroids are not specifically predicted based on animal data but will be examined in an exploratory manner.)
  • Acute alcohol-induced increases in serum levels of allopregnanolone and THDOC and in plasma levels of GABA will be directly correlated with the magnitude of acute behavioral responses to alcohol. Acute alcohol-induced decreases in serum levels of PS will be directly correlated with the magnitude of acute behavioral responses to alcohol. Correlations between alcohol-induced changes in other neurosteroids and changes in behavior are not specifically predicted but will be examined in an exploratory manner.
  • Pregnenolone, compared to placebo, pre-treatment will antagonize the acute effects of alcohol on the behavioral measures.
Read the detailed description
  1. BACKGROUND Neurosteroid Responses to Alcohol Administration: Alcohol likely interacts with the brain GABA-A receptor complex via two distinct manners: a direct effect (Grobin et al 1998), and an indirect effect, which is secondary to alterations in levels of endogenous GABA-A receptor-active neurosteroids or in levels of GABA itself (Morrow et al 1999). Indeed, alcohol's effects on neurosteroid and GABA levels may represent a novel and important mechanism of alcohol's actions (Morrow et al 1999). Acute alcohol administration significantly increases cerebral cortex (700%) and circulating (600%) levels of allopregnanolone, a potent GABA-A receptor agonist neurosteroid, in male rats (Morrow et al 1999). The magnitude of the observed alcohol-induced increase in allopregnanolone levels is sufficient to enhance GABA'ergic neurotransmission and to exert anxiolytic, sedative and anticonvulsant effects. Indeed, alcohol-induced increases in cerebral cortex allopregnanolone levels are significantly correlated with alcohol's hypnotic effects in rats (VanDoren et al 2000), and the time course of alcohol-induced increases in cerebral cortex allopregnanolone levels correlates well with many of alcohol's behavioral effects (VanDoren et al 2000); (Morrow et al 1999). Alcohol's effects on other neurosteroids have been poorly studied, although preliminary data suggest that alcohol dramatically lowers brain levels of PS (a GABA-A receptor antagonist neurosteroid) (Corpechot et al 1983) and increases brain levels of THDOC (a GABA-A receptor agonist neurosteroid) (Barbaccia et al 1999) in rats. In the latter study, THDOC and allopregnanolone levels were increased to a significantly greater extent in alcohol-preferring, compared to non-preferring rats, supporting a role of these neurosteroids in modulating alcohol's reinforcing effects (Barbaccia et al 1999) and in determining individual susceptibility to alcoholism. Regarding levels of GABA itself, acute alcohol administration raises total brain GABA levels in rats (Kulonen 1983) and raises plasma GABA levels in normal humans (Bannister et al 1988) (however, see: (Moss et al 1990)), although the acute behavioral correlates of these changes have not been well-characterized. Also, interactions between GABA changes and changes in neurosteroid levels have been poorly characterized. These data suggest that alcohol-induced changes in allopregnanolone (and perhaps PS, THDOC, other neurosteroids and GABA) levels are important contributors to alcohol's behavioral actions in rodents. Surprisingly, to our knowledge, no studies have yet assessed the effects of acute alcohol administration on neurosteroids in humans and the relationship of these biochemical effects to alcohol's behavioural effects, and few have assessed alcohol's effects on GABA levels.

Pharmacological Manipulation of Neurosteroid Levels Alters the Behavioral and Biological Effects of Alcohol and Other Sedative-Hypnotics: Pregnenolone and PS block the "anxiolytic" effect of alcohol in mice (Melchior and Ritzmann 1994), and these steroids, as well as DHEA and DHEA-S (which are GABA-A receptor antagonist/ inverse agonist neurosteroids), block the memory-impairing effect of alcohol in mice (Melchior and Ritzmann 1996). PS pre-treatment also significantly attenuates alcohol-induced sedation, hypnosis and incoordination in rats, whereas these alcohol effects are potentiated by pre-treatment with allopregnanolone (Czlonkowska et al 2000). In rats, PS also blocks sedation/hypnosis induced by barbiturates (Majewska et al 1989) and benzodiazepine-induced long-term electrophysiological depression (Akhondzadeh and Stone 1998). Pre-treatment of male rats with allopregnanolone also increases the reinforcing effects of alcohol (Janak et al 1998). This is understandable, since GABA-A receptor agonists typically facilitate voluntary ethanol consumption in animals, and since GABA-A receptor inverse agonists typically curtail ethanol consumption (reviewed in: (Grobin et al 1998)). These findings are consistent with a GABA-A receptor agonist effect of allopregnanolone and with an antagonist effect of pregnenolone, PS, DHEA and DHEA-S. In addition to direct antagonist effects, PS influences GABA-A receptor affinity and number in a manner opposite to that seen with alcohol (Majewska 1988). No studies in humans, to our knowledge, have followed up on these findings in animals by examining the effects of pharmacological neurosteroid manipulation on behavioral responses to acute alcohol ingestion. However, we have previously found that pregnenolone pre-treatment significantly antagonizes certain acute effects of benzodiazepines (which also act directly at the GABA-A receptor complex) in healthy humans (Meieran et al in review, 2002). In that study, we found that pregnenolone significantly attenuated diazepam's sedative effects (Meieran et al in review, 2002), consistent with pregnenolone's role as a GABA-A receptor antagonist/ inverse agonist.

Being tested
Pregnenolone
Keywords
NIAAA, Alcohol, Neurosteroids, Intoxication
Medical subject headings
Alcoholic Intoxication

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PregnenoloneDietary supplement

    30mg of pregnenolone administered orally, once, at 2 of 5 study visits.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Behavioural Measures of Alcohol Intoxication, such as the Weingartner Verbal Memory Test, and the BVMT-R Visual Memory Test.

    Measured: Behavioural measures are assessed within 2 hours of alcohol administration.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Feb 2008 (estimated)
  2. Study startMay 2004
  3. Primary completionJan 2009 (estimated)
  4. Study completionMar 2009 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
92 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00608686
Sponsor's protocol ID
NIAAA-WOLKOWITZ-AA013929
Other IDs
NIH grant 5R01AA013929-04
Status last verified
Dec 2008
First submitted
26 Jan 2008
Last updated
19 Dec 2008
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Pregnenolone in people with Alcohol Intoxication, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA) at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 Dec 2008. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Behavioural Measures of Alcohol Intoxication, such as the Weingartner Verbal Memory Test, and the BVMT-R Visual Memory Test. (time frame: Behavioural measures are assessed within 2 hours of alcohol administration.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2008.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in